NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its investigational product candidate, NGX-4010, for the management of pain due to postherpetic neuralgia (PHN).

More: continued here

This entry was posted on Monday, October 27th, 2008 at 2:10 am and is filed under Pain / Anesthetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.